Hormonal
Oxyntomodulin (OXM) induces superior body weight loss compared to selective GLP-1 receptor agonists by simultaneously activating both GLP-1 and glucagon receptors, thereby suppressing food intake and increasing energy expenditure.
Oxyntomodulin (OXM) is a gut-derived hormone that activates both GLP-1 and glucagon receptors. Clinical studies show that administering OXM subcutaneously three times daily before meals leads to modest but significant weight loss (approx. 2.3 kg over 4 weeks) in overweight individuals. It also improves glucose tolerance in Type 2 Diabetes patients. The dual receptor activation is key: GLP-1 reduces appetite and slows gastric emptying, while glucagon receptor activation may increase energy expenditure. However, the short half-life requires frequent dosing, and potential side effects like nausea must be managed.
Oxyntomodulin (OXM) is a peptide hormone released from the gut in post-prandial state that activates both the glucagon-like peptide-1 receptor (GLP1R) and the glucagon receptor (GCGR) resulting in superior body weight lowering to selective GLP1R agonists. OXM reduces food intake and increases energy expenditure in humans.
Why this rating
Based on human clinical trials (acute and chronic) and robust preclinical data, though long-term safety and optimal dosing ratios are still being defined.
Source
Action and therapeutic potential of oxyntomodulin
Alessandro Pocai · Molecular Metabolism · 2013
DOI 10.1016/j.molmet.2013.12.001
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →